J. Mongkolsapaya

The paper investigates how multivalent interactions between SARS-CoV-2 spike protein, ACE2 receptor, and patient-derived antibodies influence viral entry and antibody inhibition.

This paper develops a bivalent binding model to analyze how molecular reach affects SARS-CoV-2 neutralization potency across antibodies.

The paper uses deep mutational scanning to analyze dengue virus NS5, identifying conserved residues and potential plasticity in its replicase activity, with implications for antiviral strategies.

The paper shows that PDE12 inhibitors increase RNAseL activity and inhibit replication of multiple RNA viruses including SARS-CoV-2 in vitro and in vivo.

This study shows that BA.4 and BA.5 variants are more resistant to neutralization by vaccine and BA.1 immune sera compared to BA.1 and BA.2.

This study characterizes the structure, conformation, and glycosylation of the SARS-CoV-2 spike protein expressed by the ChAdOx1 nCoV-19/AZD1222 vaccine, confirming its native-like properties.

This paper identifies CR3022 as a monoclonal antibody that neutralizes SARS-CoV-2 by destroying its prefusion Spike conformation, suggesting therapeutic potential.

This paper identifies an antibody, EY6A, from a convalescent patient that neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1 by binding a conserved epitope on the Spike protein.

This study presents high-resolution cryo-EM structures of immature and mature flaviviruses, revealing structural changes during maturation and the role of pH in conformational rearrangements.

This study examines T cell immunity in UK COVID-19 patients, finding stronger and broader memory T cell responses in severe cases, with implications for vaccine design.